Fusion Pharmaceuticals Inc (FUSN)

$21.42 0.10 (0.47%)

16:00 EDT FUSN Stock Quote Delayed 30 Minutes

FUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q4 2023

By InvestorPlace Earnings Mar 20, 2024

FUSN stock results show that Fusion Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.

Why Is Fusion Pharmaceuticals (FUSN) Stock Up 101% Today?

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

7 Low-Cost Call Options With High-Profit Potential

More Articles

Volume:

Previous Close -

Market Cap 1.37B

PE Ratio -47.60

EPS -0.45

Volume (Avg. Vol.) 1.87M

Day's Range $21.32 - $21.49

52-Week Range $2.31 - $21.55

Dividend & Yield N/A (N/A)

FUSN Stock Predictions, Articles, and Fusion Pharmaceuticals Inc News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Jan 5, 2024

Pre-market stock movers are worth checking on Friday as we lay out all of the biggest stories worth keeping tabs on this morning!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Feb 14, 2023

It's time to start another day of trading with a breakdown of the biggest pre-market stock movers investors need to watch for Tuesday!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Jul 29, 2021

Good morning! We're kicking off another busy day of trading with a dive into the biggest pre-market stock movers for Thursday.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Jun 15, 2021

Welcome back, traders, and good morning! We're starting off the day with a look at the biggest pre-market stock movers for Tuesday.

AstraZeneca to Buy Fusion Pharma for Up to $2.4 Billion

From Bloomberg Mar 19, 2024

AstraZeneca Plc agreed to buy Fusion Pharmaceuticals Inc. for as much as $2.4 billion as it seeks to transform cancer treatment by replacing traditional methods like chemotherapy with more targeted approaches.

Investors growing more bullish on SMID cap biotech stocks (NASDAQ:ALNY)

From Seeking Alpha Feb 4, 2024

Investors are more bullish about small and mid-cap biotech stocks this year, with Merus (MRUS) and Fusion (FUSN) viewed as most likely to outperform, according to TD Cowen.

Fusion issues pipeline update, says new plant now fully operational (NASDAQ:FUSN)

From Seeking Alpha Jan 4, 2024

Fusion Pharmaceuticals (FUSN) issued an update on its pipeline, noting that its radiopharmaceuticals manufacturing facility is now fully operational. The new ma

Fusion Pharma stock gains as Raymond James upgrades on M&A

From Seeking Alpha Dec 27, 2023

Fusion Pharmaceuticals (FUSN) rises to a new 52-week high as Raymond James upgrades the biotech citing recent M&A activity in the radiopharma space. Read more here.

JonesTrading Sticks to Its Buy Rating for Fusion Pharmaceuticals (FUSN)

From TipRanks Nov 10, 2022

JonesTrading analyst Justin Walsh maintained a Buy rating on Fusion Pharmaceuticals (FUSN – Research Report) on November 8 and set a price target of $10.00. T...

Fusion Pharmaceuticals (FUSN) Initiated with a Buy at JonesTrading

From TipRanks Sep 6, 2022

In a report released today, Justin Walsh from JonesTrading initiated coverage with a Buy rating on Fusion Pharmaceuticals (FUSN – Research Report) and a price...

ADVERTISEMENT